CO Depositi SEC - Global Cord Blood Corp- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

CIK

1467808

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Global Cord Blood Corp

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

September 2, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.
August 14, 2025	NT 20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-34541 CUSIP Number: 356390104 (Check One): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran
June 3, 2025	EX-99.1	SUMMONS Exhibit 99.1 Commercial in Confidence To: All Shareholders 3 June 2025 Dear Shareholders, Grant Thornton Specialist Services (Cayman) Limited 2nd floor Century Yard, Cricket Square, PO Box 1044, Grand Cayman, KY1-1102 Cayman Islands T +1 (345) 949 8588 F +1 (345) 949 7120 Global Cord Blood Corporation (In Provisional Liquidation) (the “Company”) Cause No: FSD 106 of 2022 (IKJ) Cayman Islands compa
June 3, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
March 4, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-3454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
February 12, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
February 12, 2025	EX-99.1	Commercial in Confidence Exhibit 99.1 Commercial in Confidence To: All purported Shareholders of Global Cord Blood Corporation Limited (in Provisional Liquidation) 11 February 2025 Dear Shareholders, Grant Thornton Specialist Services (Cayman) Limited 2nd floor Century Yard, Cricket Square, PO Box 1044, Grand Cayman, KY1-1102 Cayman Islands T +1 (345) 949 8588 F +1 (345) 949 7120 Global Cord Blood Corporation (In Provisio
December 3, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
September 4, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.
August 9, 2024	NT 20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-34541 CUSIP Number: 356390104 (Check One): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran
July 26, 2024	EX-99.1	Commercial in Confidence Exhibit 99.1 Commercial in Confidence To: All Shareholders 25 July 2024 Dear Shareholders, Grant Thornton Specialist Services (Cayman) Limited 2nd floor Century Yard, Cricket Square, PO Box 1044, Grand Cayman, KY1-1102 Cayman Islands T +1 (345) 949 8588 F +1 (345) 949 7120 Global Cord Blood Corporation (In Provisional Liquidation) (the “Company”) Cause No: FSD 106 of 2022 (IKJ) Cayman Islands comp
July 26, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
July 19, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
July 19, 2024	EX-99.1	AMENDED SUMMONS Exhibit 99.1 Commercial in Confidence To: All Shareholders 18 July 2024 Dear Shareholders, Grant Thornton Specialist Services (Cayman) Limited 2nd floor Century Yard, Cricket Square, PO Box 1044, Grand Cayman, KY1-1102 Cayman Islands T +1 (345) 949 8588 F +1 (345) 949 7120 Global Cord Blood Corporation (In Provisional Liquidation) (the “Company”) Cause No: FSD 106 of 2022 (IKJ) Cayman Islands comp
June 4, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
June 4, 2024	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-3454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
June 4, 2024	EX-99.1	RESPONSES TO QUERIES GLOBAL CORD BLOOD CORPORATION (IN PROVISIONAL LIQUIDATION) Exhibit 99.1 Commercial in Confidence To: All Shareholders By e-mail 29 May 2024 Dear Shareholders, Grant Thornton Specialist Services (Cayman) Limited 2nd floor Century Yard, Cricket Square, PO Box 1044, Grand Cayman, KY1-1102 Cayman Islands T +1 (345) 949 8588 F +1 (345) 949 7120 Nobel Cord Blood Corporation (In Provisional Liquidation) (the “Company”) Cause No: FSD 106 of 2022 (IKJ) Cayman Isla
May 31, 2024	EX-99.1	RESPONSES TO QUERIES GLOBAL CORD BLOOD CORPORATION (IN PROVISIONAL LIQUIDATION) Exhibit 99.1 Commercial in Confidence To: All Shareholders By e-mail 29 May 2024 Dear Shareholders, Grant Thornton Specialist Services (Cayman) Limited 2nd floor Century Yard, Cricket Square, PO Box 1044, Grand Cayman, KY1-1102 Cayman Islands T +1 (345) 949 8588 F +1 (345) 949 7120 Nobel Cord Blood Corporation (In Provisional Liquidation) (the “Company”) Cause No: FSD 106 of 2022 (IKJ) Cayman Isla
May 31, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. (
April 25, 2024	EX-99.1	Global Cord Blood Corporation – in Provisional Liquidation Minutes of Call for Adjourned EGM of 23 April 2024 Exhibit 99.1 Global Cord Blood Corporation – in Provisional Liquidation Minutes of Call for Adjourned EGM of 23 April 2024 Location The date is 23 April 2024, and it is 07:45 AM GMT - 5 hours at the offices of Grant Thornton Specialist Services (Cayman) Limited, 2nd floor, Century Yard, Cricket Square, Grand Cayman, Cayman Islands KY1-1102. Introduction John Royle (the “Chairperson”), one of the J
April 25, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
April 17, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
April 17, 2024	EX-99.1	GLOBAL CORD BLOOD CORPORATION (IN PROVISIONAL LIQUIDATION) (Incorporated in the Cayman Islands with limited liability) (OTC US: CORBF) Exhibit 99.1 GLOBAL CORD BLOOD CORPORATION (IN PROVISIONAL LIQUIDATION) (Incorporated in the Cayman Islands with limited liability) (OTC US: CORBF) 2nd floor, Century Yard, Cricket Square Grand Cayman, KYl-9010, Cayman Islands Reference is made to the Notice of Extraordinary General Meeting dated 18 March 2024, convening the Extraordinary General Meeting (“EGM”) of Global Cord Blood Corporation (I
March 19, 2024	EX-99.1	GLOBAL CORD BLOOD CORPORATION (IN PROVISIONAL LIQUIDATION) (Incorporated in the Cayman Islands with limited liability) (OTC US: CORBF) 2nd floor, Century Yard, Cricket Square Grand Cayman, KYl-9010, Cayman Islands NOTICE OF EXTRAORDINARY GENERAL MEET Exhibit 99.1 GLOBAL CORD BLOOD CORPORATION (IN PROVISIONAL LIQUIDATION) (Incorporated in the Cayman Islands with limited liability) (OTC US: CORBF) 2nd floor, Century Yard, Cricket Square Grand Cayman, KYl-9010, Cayman Islands NOTICE OF EXTRAORDINARY GENERAL MEETING To be held on 16 April 2024 (or any adjourned or postponed meeting thereof) NOTICE IS HEREBY GIVEN that an extraordinary general meet
March 19, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
March 11, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
March 11, 2024	SC 13G/A	CORBF / Global Cord Blood Corporation / Oasis Management Co Ltd. - GLOBAL CORD BLOOD CORP Passive Investment SC 13G/A 1 p24-1124sc13ga.htm GLOBAL CORD BLOOD CORP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Global Cord Blood Corporation (Name of Issuer) Ordinary shares, par value $0.0001 per share (Title of Class of Securities) G39342103 (CUSIP Number) February 29, 2024 (Date of event which requires filing of this st
February 14, 2024	SC 13G/A	CO / Global Cord Blood Corp / Oasis Management Co Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class Securities) G39342103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 12, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
December 4, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
September 29, 2023	EX-99.2	HEADNOTE Jurisdiction to set aside or vary a judgment before the order giving effect to it is drawn up-inherent jurisdiction proof fraud not required-Grand Court Act (2015 Revision), section 11(1) REASONS FOR DECISION Exhbit 99.2 IN THE GRAND COURT OF THE CAYMAN ISLANDS FINANCIAL SERVICES DIVISION CAUSE NO: FSD 108 of 2022 (IKJ) IN THE MATTER OF THE SECTION 92 OF THE COMPANIES ACT (2022 REVISION) AND IN THE MATTER OF GLOBAL CORD BLOOD CORPORATION Appearances: Mr David Chivers KC and Ms Fleur O'Driscoll and Mr Alan Quigley of Forbes Hare on behalf of Blue Ocean Structure Investment Limited (the Petitioner) Mr Vi
September 29, 2023	EX-99.1	AND GLOBAL CORD BLOOD CORPORATION Exhibit 99.1 IN THE GRAND COURT OF THE CAYMAN ISLANDS FINANCIAL SERVICES DIVISION CAUSE NO. FSD 108 OF 2022 (IKJ) IN THE MATTER OF SECTION 92 OF THE COMPANIES ACT (2023 REVISION) AND IN THE MATTER OF GLOBAL CORD BLOOD CORPORATION BETWEEN: BLUE OCEAN STRUCTURE INVESTMENT COMPANY LIMITED PETITIONER AND GLOBAL CORD BLOOD CORPORATION RESPONDENT ORDER UPON Blue Ocean Structure Investment Company Limite
September 29, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.
September 5, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.
August 11, 2023	NT 20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-34541 CUSIP Number: G39342103 (Check One): ☐ Form 10-K ☑ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran
June 22, 2023	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange ("NYSE" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Ordinary Shares (the "Common Stock") of Global Cord Blood Corporation (the "Company") from listing and registration on the Exchange on July 3, 2023, pursuant to the provisions of Rule 12d2-2(b) because, in the opinion of the Exchange, the Common Stock is no longer suitable for continued listing and trading on the NYSE.
June 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
April 10, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
March 3, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 6-K 1 a6k.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of Chi
February 17, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-3 6-K 1 a6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central
February 14, 2023	SC 13G	CO / China Cord Blood Corp. / Oasis Management Co Ltd. - SC 13G Passive Investment SC 13G 1 brhc10047885sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class Securities) G39342103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the
February 3, 2023	SC 13G/A	CO / China Cord Blood Corp. / JAYHAWK CAPITAL MANAGEMENT, L.L.C. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment No. 18 Under the Securities Exchange Act of 1934* Global Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) G39342103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
February 3, 2023	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including all amendments thereto) with respect to the ordinary shares, par value US$0.0001 per share, of Global Cord Blood Corporation, and that this Joint F
February 3, 2023	SC 13G	CO / China Cord Blood Corp. / Pacific Alliance Group Ltd - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
December 2, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
October 31, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-34 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.
October 21, 2022	EX-99.1	Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited, as joint provisional liquidators (the “JPLs”) of Global Cord Blood Corporation (the “ Exhibit 99.1 Commercial in confidence Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited, as joint provisional liquidators (the “JPLs”) of Global Cord Blood Corporation (the “Company”) JPL Responses to Common Questions About the Provisional Liquidation October 20, 2022 The JPLs’ respons
October 21, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-34 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.
September 26, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.
September 26, 2022	EX-99.1	Schedule 1 Table of Affidavits & Affirmations Exhibit 99.1 ORDER FSD2022-0108 Page 1 of 9 2022-09-22 IN THE GRAND COURT OF THE CAYMAN ISLANDS Financial Services DIVISION FSD CAUSE NO.108 OF 2022 (IKJ) IN THE MATTER OF SECTION 92 OF THE COMPANIES ACT (2022 REVISION) AND IN THE MATTER OF GLOBAL CORD BLOOD CORPORATION BETWEEN Blue Ocean Structure Investment Company Limited PETITIONER and Global Cord Blood Corporation Respondent ORDER UPON the ap
September 26, 2022	EX-99.2	Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands Exhibit 99.2 Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands HONG KONG, China, September 26, 2022 - Global Cord Blood Corporation (NYSE: CO) (?GCBC? or the ?Company?), China?s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced
September 23, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 11) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Num
September 23, 2022	EX-99.A	Exhibit A – Order attached thereto as Annex A Exhibit A ORDER FSD2022-0108 Page 1 of 9 2022-09-22 IN THE GRAND COURT OF THE CAYMAN ISLANDS Financial Services DIVISION FSD CAUSE NO.
August 24, 2022	EX-99.A	ANNEX A FSD2022-0108 Page 1 of 11 2022-08-23 Exhibit A Digitally signed by Advance Performance Exponents Inc Date: 2022.
August 24, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 10) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Num
August 16, 2022	EX-15.1	Consent of KPMG Huazhen LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements (No. 333-183143 and No. 333-233880) on Form F-3 of our reports dated August 16, 2022, with respect to the consolidated financial statements of Global Cord Blood Corporation and the effectiveness of internal control over financial reporting. /s/ KPMG Huaz
August 16, 2022	EX-12.1	Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.1 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc
August 16, 2022	EX-12.2	Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.2 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which su
August 16, 2022	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
August 16, 2022	EX-13.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Global Cord Blood Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The annual report on Form 20-F for the year en
August 16, 2022	EX-15.2	Consent of Commerce & Finance Law Offices Exhibit 15.2 ? ? ? ? ? ? ? Commerce & Finance Law Offices 12-14th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China Tel:+86 10 6563 7181 Fax: +86 10 6569 3838 Email: [email protected] Web: www.tongshang.com August 16, 2022 Global Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Dear Sirs/Madams: We consent to the refere
August 2, 2022	NT 20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34541 CUSIP NUMBER: G39342103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 6, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
July 6, 2022	EX-99.1	Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM Exhibit 99.1 Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM HONG KONG, China, July 6, 2022 ? Global Cord Blood Corporation (NYSE: CO, ?GCBC? or the ?Company?), China?s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the
July 5, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
July 5, 2022	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22?Non-GAAP Operating Inco
June 27, 2022	EX-4.1	Form of First Amendment to Stock Purchase Agreement each dated as of June 27, 2022 by and among the Company, Cellenkos, Inc. and the stockholders of Cellenkos party thereto. Exhibit 4.1 FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT THIS FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT (this ?Amendment?) is entered into and effective as of June 27, 2022 by and among Global Cord Blood Corporation, a Cayman Islands exempted company (?Buyer?), Cellenkos, Inc., a Delaware corporation (the ?Company?), and ????????????????????(?Seller?). Each of Buyer, the Company and Seller is her
June 27, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
June 22, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 9) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
June 16, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
June 16, 2022	EX-99.1	Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened Exhibit 99.1 Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened HONG KONG, China, June 16, 2022 ? Global Cord Blood Corporation (NYSE: CO, ?GCBC? or the ?Company?), China?s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that on June 3, 2022 Blue Ocean Structure Investment Company L
June 16, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
June 16, 2022	EX-99.A	Exhibit A – Press Release Exhibit A Shareholders Led by Blue Ocean Announce Successful Results of Extraordinary General Meeting of Global Cord Blood Corporation (New York ? 16 June, 2022) Blue Ocean Structure Investment Company Ltd.
June 15, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
June 15, 2022	EX-99.A	Rules of Conduct Extraordinary General Meeting of Shareholders of Global Cord Blood Corporation Exhibit A Rules of Conduct Extraordinary General Meeting of Shareholders of Global Cord Blood Corporation These Rules of Conduct (these “Rules”) are for the Extraordinary General Meeting of Shareholders (the “Meeting”) of Global Cord Blood Corporation (the “Company”), convened by Blue Ocean Structure Investment Co Ltd (the “Convening Shareholder”) with the support of certain other shareholders of the Company.
June 3, 2022	EX-99.A	NOTICE OF EXTRAORDINARY GENERAL MEETING to Be Held on June 16, 2022 (or any adjourned or postponed meeting thereof) Exhibit A To: The Shareholders and the Board of Global Cord Blood Corporation With copies to: Conyers Trust Company (Cayman) Limited SIX, 2nd Floor, Cricket Square, PO Box 2681, Grand Cayman KY1-1111 Cayman Islands Attention: The Board of the Company NOTICE OF EXTRAORDINARY GENERAL MEETING to Be Held on June 16, 2022 (or any adjourned or postponed meeting thereof) Dear Sirs, NOTICE IS HEREBY GIVEN
June 3, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
May 31, 2022	SC 13D/A	CO / China Cord Blood Corp. / Golden Meditech Stem Cells (BVI) Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Global Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 (Title of Class of Securities) G39342103 (CUSIP Number) Yuen Kam 48th Floor, Bank of China Tower 1 Garden Road, Central Hong Kong S.A.R. (852) 3605-8180 (Name, Address and T
May 27, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
May 23, 2022	EX-99.A	Blue Ocean Comments on Fraudulent Claims from Conflicted Party Golden Meditech Regarding Global Cord Blood Corporation Recent Filing Only Intended as a Distraction to Shareholders and has No Impact on Blue Ocean Campaign to STOP the Cellenkos Transac Exhibit A Blue Ocean Comments on Fraudulent Claims from Conflicted Party Golden Meditech Regarding Global Cord Blood Corporation Recent Filing Only Intended as a Distraction to Shareholders and has No Impact on Blue Ocean Campaign to STOP the Cellenkos Transaction (New York – 23 May, 2022) Blue Ocean Structure Investment Company Ltd.
May 23, 2022	EX-99.1	Dated this 30 day of March 2018 BETWEEN : BLUE OCEAN STRUCTURE INVESTMENT COMPANY LIMITED as Chargor GOLDEN MEDITECH STEM CELLS (BVI) COMPANY LIMITED as Chargee CHARGE OVER SHARES in Global Cord Blood Corporation (formerly known as China Cord Blood C Exhibit 99.1 Dated this 30 day of March 2018 BETWEEN : BLUE OCEAN STRUCTURE INVESTMENT COMPANY LIMITED as Chargor AND GOLDEN MEDITECH STEM CELLS (BVI) COMPANY LIMITED as Chargee CHARGE OVER SHARES in Global Cord Blood Corporation (formerly known as China Cord Blood Corporation) TABLE OF CONTENTS 1 INTERPRETATION 4 2 CHARGOR?S REPRESENTATIONS AND WARRANTIES 6 3 COVENANT TO PAY 8 4 CHARGOR?S COVENAN
May 23, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
May 23, 2022	SC 13D	CO / China Cord Blood Corp. / Golden Meditech Stem Cells (BVI) Co Ltd - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Global Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 (Title of Class of Securities) G39342103 (CUSIP Number) Yuen Kam 48th Floor, Bank of China Tower 1 Garden Road, Central Hong Kong S.A.R. (852) 3605-8180 (Name, Address and Telephone Number of
May 23, 2022	EX-99.B	Exhibit B – Agreement of Joint Filing. EXHIBIT B AGREEMENT OF JOINT FILING The parties listed below agree that the amendment of Schedule 13D to which this agreement is attached as an exhibit (including any amendments thereto signed by the parties to this joint filing agreement), shall be filed on behalf of each of them.
May 23, 2022	EX-99.2	JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934 (the ?Act?), as amended, the undersigned agree that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares of Global Cord Blood Corporation, a Cayman Islands Company,
May 20, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
May 20, 2022	EX-99.A	STOCK PURCHASE AGREEMENT EXHIBIT A STOCK PURCHASE AGREEMENT Exhibit A Execution Version SHARE Purchase Agreement by and between DENDREON PHARMACEUTICALS LLC, and AMC FUND, L.
May 13, 2022	EX-99.A	EX PARTE ORDER Exhibit A EXHIBIT A EX PARTE ORDER IN THE GRAND COURT OF THE CAYMAN ISLANDS Financial Services DIVISION FSD CAUSE NO.
May 13, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
May 9, 2022	EX-99.A	notice of PETITIOn TO WIND UP EXHIBIT A notice of PETITIOn TO WIND UP Exhibit A IN THE GRAND COURT OF THE CAYMAN ISLANDS Financial Services DIVISION FSD CAUSE NO.
May 9, 2022	SC 13D/A	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) GLOBAL CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) G21107100 (CUSIP Number) Cheng Zeng No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274734 (Name, Address and Telephone Numb
April 29, 2022	EX-4.6	Stock Purchase Agreement, dated April 29, 2022, among the Registrant, Cellenkos, Inc. and Vyserion Limited (incorporated herein by reference to Exhibit 4.6 of our Form 6-K (File No. 001-34541) furnished with the Securities and Exchange Commission on April 29, 2022) Exhibit 4.6 FINAL VERSION STOCK PURCHASE AGREEMENT BY AND AMONG GLOBAL CORD BLOOD CORPORATION, CELLENKOS, INC. AND VYSERION LIMITED April 29, 2022 TABLE OF CONTENTS Page Article 1 Sale and Purchase of Common Stock and assignment of warrant 1 1.1 Sale and Purchase of Common Stock 1 1.2 Assignment of Warrant 1 Article 2 PURCHASE PRICE; treatment of company optionS 2 2.1 Purchase Price 2 2.2 Closing
April 29, 2022	EX-4.5	Stock Purchase Agreement dated as of April 29, 2022 by and among the Company, Cellenkos, Inc. and Rocelo LLC. Exhibit 4.5 FINAL VERSION STOCK PURCHASE AGREEMENT BY AND AMONG GLOBAL CORD BLOOD CORPORATION, CELLENKOS HOLDINGS L.P., CELLENKOS, INC. AND ROCELO LLC April 29, 2022 TABLE OF CONTENTS Page Article 1 Sale and Purchase of Common Stock 1 Article 2 PURCHASE PRICE; treatment of company optionS 1 2.1 Purchase Price 1 2.2 Closing Payments and Issuances 1 2.3 Treatment of Company Options 2 Article 3 REPRE
April 29, 2022	EX-4.1	Stock Purchase Agreement dated as of April 29, 2022 by and among the Company, Cellenkos, Inc. and Golden Meditech (BVI) Company Limited. Exhibit 4.1 FINAL VERSION STOCK PURCHASE AGREEMENT BY AND AMONG GLOBAL CORD BLOOD CORPORATION, CELLENKOS, INC. AND GOLDEN MEDITECH (BVI) COMPANY LIMITED April 29, 2022 TABLE OF CONTENTS Page Article 1 Sale and Purchase of Common Stock and assignment of warrant 1 1.1 Sale and Purchase of Common Stock 1 1.2 Assignment of Warrant 1 Article 2 PURCHASE PRICE; treatment of company optionS 2 2.1 Purchase
April 29, 2022	EX-4.3	Stock Purchase Agreement dated as of April 29, 2022 by and among the Company, Cellenkos, Inc., and Leong Kim Chuan. Exhibit 4.3 FINAL VERSION STOCK PURCHASE AGREEMENT BY AND AMONG GLOBAL CORD BLOOD CORPORATION, CELLENKOS, INC. AND LEONG KIM CHUAN April 29, 2022 TABLE OF CONTENTS Page Article 1 Sale and Purchase of Common Stock 1 Article 2 PURCHASE PRICE; treatment of company optionS 1 2.1 Purchase Price 1 2.2 Closing Payments and Issuances 1 2.3 Treatment of Company Options 2 Article 3 REPRESENTATIONS AND WARRA
April 29, 2022	EX-4.4	Stock Purchase Agreement dated as of April 29, 2022 by and among the Company, Cellenkos, Inc., The Paul Brooke 2012 Family Trust and The Paul Brooke and Kathleen McCarragher 2012 Family Trust. Exhibit 4.4 STOCK PURCHASE AGREEMENT BY AND AMONG GLOBAL CORD BLOOD CORPORATION, CELLENKOS HOLDINGS L.P., CELLENKOS, INC., THE PAUL BROOKE 2012 FAMILY TRUST AND THE PAUL BROOKE AND KATHLEEN MCCARRAGHER 2012 FAMILY TRUST April 29, 2022 TABLE OF CONTENTS Page Article 1 Sale and Purchase of Common Stock 1 Article 2 PURCHASE PRICE; treatment of company optionS 2 2.1 Purchase Price 2 2.2 Closing Paymen
April 29, 2022	EX-99.1	Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights Exhibit 99.1 Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights HONG KONG, China, April, 29, 2022 ? Global Cord Blood Corporation (NYSE: CO, ?GCBC? or the ?Company?), China?s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Com
April 29, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-3454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
April 29, 2022	EX-4.2	Stock Purchase Agreement dated as of April 29, 2022 by and among the Company, Cellenkos, Inc., HL succors and HL succors ZN. Exhibit 4.2 FINAL VERSION STOCK PURCHASE AGREEMENT BY AND AMONG GLOBAL CORD BLOOD CORPORATION, CELLENKOS, INC. HL SUCCORS AND HL SUCCORS ZN April 29, 2022 TABLE OF CONTENTS Page Article 1 Sale and Purchase of Common Stock 1 Article 2 PURCHASE PRICE; treatment of company optionS 1 2.1 Purchase Price 1 2.2 Closing Payments and Issuances 1 2.3 Treatment of Company Options 2 Article 3 REPRESENTATIONS
April 29, 2022	EX-4.9	Employment Agreement, dated April 29, 2022, between the Registrant and Leong Kim Chuan (incorporated herein by reference to Exhibit 4.9 of our Form 6-K (File No. 001-34541) furnished with the Securities and Exchange Commission on April 29, 2022) Exhibit 4.9 FINAL VERSION EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of this 29 day of April 2022, by and between, Global Cord Blood Corporation, a Cayman Islands corporation (the ?Company?), and Leong Kim Chuan (the ?Executive?). W I T N E S S E T H : WHEREAS, in connection with the transactions contemplated by the Acquisition Agreement and the O
April 29, 2022	EX-4.10	Partnership Agreement to be entered into by and among Cellenkos GP Limited, a company incorporated under the laws of the British Virgin Islands, as General Partner and subsidiary of the Company and the limited partners party thereto from time to time. Exhibit 4.10 FINAL VERSION LIMITED PARTNERSHIP AGREEMENT of CELLENKOS HOLDINGS L.P. dated as of [ ] THE PARTNERSHIP INTERESTS (THE ?INTERESTS?) REFERRED TO IN THIS LIMITED PARTNERSHIP AGREEMENT (THE ?AGREEMENT?) HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES, OR ANY OTHER APPLICABLE S
April 29, 2022	EX-4.8	Employment Agreement, dated April 29, 2022, between the Registrant and Dr. Simrit Parmar (incorporated herein by reference to Exhibit 4.8 of our Form 6-K (File No. 001-34541) furnished with the Securities and Exchange Commission on April 29, 2022) Exhibit 4.8 FINAL VERSION EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of this 29 day of April 2022, by and among, Global Cord Blood Corporation, a Cayman Islands corporation (the ?Company?), Cellenkos, Inc., a Delaware corporation (?Cellenkos?, together with the Company, the ?Employers? and each, an ?Employer?), and Dr. Simrit Parmar (the ?Executiv
April 29, 2022	EX-4.7	Framework Agreement, dated April 29, 2022, between the Registrant and GM Precision Medicine (BVI) Limited (incorporated by reference to Exhibit 4.7 of our Form 6-K (File No. 001-34541) furnished with the Securities and Exchange Commission on April 29, 2022) Exhibit 4.7 FINAL VERSION FRAMEWORK AGREEMENT BY AND BETWEEN GLOBAL CORD BLOOD CORPORATION AND GM PRECISION MEDICINE (BVI) LIMITED April 29, 2022 TABLE OF CONTENTS Article 1 EQUITY TRANSFER AND ASSIGNMENT 5 1.1 Assignment. 5 1.2 Equity Transfer 5 Article 2 CONSIDERATION 5 2.1 Consideration 5 2.2 Closing Payments and Issuances 5 2.3 Withholding 5 Article 3 REPRESENTATIONS AND WARRANTIES OF BVI COMP
February 28, 2022	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022 Added 18,985 New Subscribers in 3Q22 Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million) Gross Profit Up 9.8% YoY to RMB269.9 Mill Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022 Added 18,985 New Subscribers in 3Q22 Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million) Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million) Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6
February 28, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
February 15, 2022	SC 13G/A	CO / China Cord Blood Corp. / JAYHAWK CAPITAL MANAGEMENT, L.L.C. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment No. 17 Under the Securities Exchange Act of 1934* Global Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) G39342103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
December 16, 2021	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
December 16, 2021	EX-99.1	Global Cord Blood Corporation Announces Rejection of Alternate Ocean Proposal EX-99.1 2 tm2135502d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Global Cord Blood Corporation Announces Rejection of Alternate Ocean Proposal HONG KONG, China, December 16, 2021 — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that
December 7, 2021	EX-99.1	Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting EX-99.1 2 tm2134536d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting HONG KONG, China, December 7, 2021 - Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the
December 7, 2021	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-3 6-K 1 tm2134536d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1
December 3, 2021	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A (Amendment No.1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? ? FORM 6-K/A (Amendment No.1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 ? For the month of December 2021 ? Commission File Number: 001-34541 ? GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) ? 48th Floor, Bank of China Towe
November 24, 2021	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
November 24, 2021	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2022 Added 19,066 New Subscribers in 2Q22 Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million) Gross Profit Up 11.0% YoY to RMB267.5 Million ( Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2022 Added 19,066 New Subscribers in 2Q22 Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million) Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million) Operating Income Up 15.3% YoY to RMB160.5 Million ($24.9 Million) Non-GAAP Operating Income Up 14.1% YoY to RMB172.8 Milli
October 29, 2021	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-34 ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549? ? FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong
October 29, 2021	EX-99.1	GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 7, 2021 (or any TABLE OF CONTENTS Exhibit 99.1? GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 7, 2021 (or any adjourned or postponed meeting thereof) To the Shareholders of Global Cord Blood Corporation: NOTICE IS HEREBY GIVEN
August 30, 2021	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-345 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R
August 30, 2021	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2022 1Q22 Added 19,673 New Subscribers Revenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million) Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million) Ope Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2022 1Q22 Added 19,673 New Subscribers Revenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million) Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million) Operating Income Up 17.3% YoY to RMB156.6 Million ($24.2 Million) Non-GAAP Operating Income Up 15.5% YoY to RMB168.5 Million ($26.1 Million)
July 29, 2021	EX-15.2	Consent of Commerce & Finance Law Offices Exhibit 15.2 ? ? ? ? ? ? ? Commerce & Finance Law Offices 12-14th Floor, China World Office 2, No.1 Jianguomenwai Avenue, Beijing PRC; Postcode: 100004 Tel:(8610) 65637181 Fax:(8610) 65693838 Website: www.tongshang.com July 29, 2021 Global Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Dear Sirs/Madams: We consent to the reference of our name under t
July 29, 2021	EX-12.2	Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.2 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which su
July 29, 2021	EX-13.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Global Cord Blood Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The annual report on Form 20-F for the year en
July 29, 2021	EX-4.10	Non-binding proposal letter from Alternate Ocean Investment Company Limited, dated March 2, 2021 Exhibit 4.10 Confidential March 2, 2021 Board of Directors (the ?Board?) Global Cord Blood Corporation (the ?Company?) 48th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Dear Members of the Board of Directors: Alternate Ocean Investment Company Limited (?Alternate Ocean? or ?we?), a wholly-owned subsidiary of Haitong International Securities Group Limited (?Haitong Internation
July 29, 2021	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
July 29, 2021	EX-12.1	Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.1 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc
July 29, 2021	EX-15.1	Consent of KPMG Huazhen LLP EX-15.1 6 co-20210331xex15d1.htm EXHIBIT 15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements (No. 333-183143 and No. 333-233880) on Form F-3 of our reports dated July 29, 2021, with respect to the consolidated financial statements of Global Cord Blood Corporation and the effectiveness of internal con
June 28, 2021	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2021 Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2021 Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY to RMB211.1 million ($32.2 million) Conference Call to be Held on June 29, 202
June 28, 2021	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-34541 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
March 15, 2021	EX-99.1	Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal Exhibit 99.1 Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal HONG KONG, China, March 15, 2021 — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the
March 15, 2021	6-K	Current Report of Foreign Issuer - 6-K 6-K 1 a21-971816k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Roa
March 2, 2021	6-K	Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
March 2, 2021	EX-99.1	Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal Shareholders Advised to Take No Action Pending Board Review Exhibit 99.1 Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal Shareholders Advised to Take No Action Pending Board Review HONG KONG, China, March 2, 2021 ? Global Cord Blood Corporation (NYSE: CO) (?GCBC? or the ?Company?), China?s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage s
February 24, 2021	6-K	Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
February 24, 2021	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021 Added 17,802 New Subscribers in 3Q21 Conference Call to be Held on February 25, 2021, at 8:00 a.m. ET Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021 Added 17,802 New Subscribers in 3Q21 Conference Call to be Held on February 25, 2021, at 8:00 a.m. ET HONG KONG, China, February 24, 2021 — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory te
February 11, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment No. 16 Under the Securities Exchange Act of 1934* Global Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Clas UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment No. 16 Under the Securities Exchange Act of 1934* Global Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) G39342103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
February 11, 2021	EX-99.1	Global Cord Blood Corporation Announces Termination of Discussion Regarding Cordlife Merger Proposal Exhibit 99.1 Global Cord Blood Corporation Announces Termination of Discussion Regarding Cordlife Merger Proposal HONG KONG, China, February 11, 2021 — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that, in relation to the n
February 11, 2021	6-K	Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
December 9, 2020	SC 13D/A	VTR / Ventas, Inc. / Magnum Opus International (PTC) Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Global Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 (Title of Class of Securities) G39342103 (CUSIP Number) Albert Chen c/o Magnum Opus International (PTC) Limited 48th Floor, Bank of China Tower 1 Garden Road, Central Hong
December 8, 2020	6-K/A	Current Report of Foreign Issuer - 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A (Amendment No.1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Ce
December 7, 2020	EX-99.1	Global Cord Blood Corporation Announces Results of 2020 Annual General Meeting Exhibit 99.1 Global Cord Blood Corporation Announces Results of 2020 Annual General Meeting HONG KONG, China, December 7, 2020 - Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2020 Annual General Meeting,
December 7, 2020	6-K	Current Report of Foreign Issuer - 6-K 6-K 1 a20-3750016k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden
November 24, 2020	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021 Added 17,643 New Subscribers in 2Q21 Conference Call to be Held on November 25, 2020, at 8:00 a.m. ET Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021 Added 17,643 New Subscribers in 2Q21 Conference Call to be Held on November 25, 2020, at 8:00 a.m. ET HONG KONG, China, November 24, 2020 — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing,
November 24, 2020	6-K	Current Report of Foreign Issuer - 6-K 6-K 1 a20-3608016k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden
October 28, 2020	6-K	Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.
October 28, 2020	EX-99.1	GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 7, 2020 (or any Exhibit 99.1 GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 7, 2020 (or any adjourned or postponed meeting thereof) To the Shareholders of Global Cord Blood Corporation: NOTICE IS HEREBY GIVEN that the 2020 Annua
August 24, 2020	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021 Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021 1Q21 Added 17,233 New Subscribers Revenues Up 2.8% YoY to RMB280.9 Million ($39.8 Million) Gross Profit Up 4.3% YoY to RMB237.5 million ($33.6 million) Operating Income Up 18.8% YoY to RMB133.5 Million ($18.9 Million) Non-GAAP Operating Income Up 16.8% YoY to RMB145.9 Million ($20.6 Million) C
August 24, 2020	6-K	Current Report of Foreign Issuer - 6-K 6-K 1 a20-2888416k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden R
July 29, 2020	20-F	- 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH
July 29, 2020	EX-12.1	Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.1 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc
July 29, 2020	EX-12.2	Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.2 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which su
July 29, 2020	EX-2.4	Description of Securities Exhibit 2.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General Global Cord Blood Corporation (formerly named China Cord Blood Corporation or “CCBC”), has one class of securities, ordinary shares, registered under Section 12 of the Securities Exchange Act of 1934, as amended. As of the date of this annual report, our authorize
July 29, 2020	EX-15.1	Consent of KPMG Huazhen LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors Global Cord Blood Corporation We consent to the incorporation by reference in the Registration Statements (No. 333-183143 and No. 333-233880) on Form F-3 of Global Cord Blood Corporation of our reports dated July 29, 2020, with respect to the consolidated balance sheets of Global Cord Blood Corporation and
July 29, 2020	EX-13.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Global Cord Blood Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The annual report on Form 20-F for the year en
July 29, 2020	EX-15.2	Consent of Commerce & Finance Law Offices Exhibit 15.2 通商律師事務所 Commerce & Finance Law Offices 6F NCI Tower, A12 Jianguomenwai Avenue, Chaoyang District, Beijing, PRC; Postcode: 100022 Tel:(8610) 65693399 Fax: (8610) 65693838 Website: www.tongshang.com July 29, 2020 Global Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Dear Sirs/Madams: We consent to the reference of our name under the
June 30, 2020	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020 Added 18,488 New Subscribers in 4Q20 4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million) 4Q20 Operating Income Increased Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020 Added 18,488 New Subscribers in 4Q20 4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million) 4Q20 Operating Income Increased by 68.1% YoY to RMB149.3 Million ($21.1 Million) Non-GAAP Operating Income Up 58.7% YoY to RMB161.7 Million ($22.8 Million) Conference Ca
June 30, 2020	6-K	Current Report of Foreign Issuer - 6-K 6-K 1 a20-2330516k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Roa
April 27, 2020	EX-99.1	Global Cord Blood Corporation Provides Further Update on COVID-19 Exhibit 99.1 Global Cord Blood Corporation Provides Further Update on COVID-19 HONG KONG, China, April 27, 2020 — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today provided an update on the impact of the 2019 novel coronavirus (“COVID-19”
April 27, 2020	6-K	Current Report of Foreign Issuer - 6-K 6-K 1 a20-1776616k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Ro
March 11, 2020	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2020 3Q20 Added 23,387 New Subscribers Revenues Up 31.7% YoY to RMB334.7 Million ($48.1 Million) Operating Income Up 65.1% YoY to RMB152.9 M Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2020 3Q20 Added 23,387 New Subscribers Revenues Up 31.7% YoY to RMB334.7 Million ($48.1 Million) Operating Income Up 65.1% YoY to RMB152.9 Million ($22.0 Million) Non-GAAP Operating Income Up 56.7% YoY to RMB165.0 Million ($23.7 Million) Conference Call to be Held on March 12,
March 11, 2020	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 a20-1207716k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Ro
February 13, 2020	SC 13G/A	VTR / Ventas, Inc. / JAYHAWK CAPITAL MANAGEMENT, L.L.C. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment No. 15 Under the Securities Exchange Act of 1934* Global Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) G39342103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
December 6, 2019	6-K/A	CO / China Cord Blood Corp. 6-K/A - Current Report of Foreign Issuer - 6-K/A 6-K/A 1 a19-1994316ka.htm 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Ban
December 5, 2019	EX-99.1	Global Cord Blood Corporation Announces Results of 2019 Annual General Meeting Exhibit 99.1 Global Cord Blood Corporation Announces Results of 2019 Annual General Meeting HONG KONG, China, December 5, 2019 - Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2019 Annual General Meeting,
December 5, 2019	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
November 26, 2019	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2020 2Q20 Added 21,551 New Subscribers Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2020 2Q20 Added 21,551 New Subscribers Revenues Up 26.9% YoY to RMB313.5 Million ($43.9 Million) Operating Income Up 37.9% YoY to RMB144.4 Million ($20.2 Million) Non-GAAP Operating Income Up 32.8% YoY to RMB156.9 Million ($22.0 Million) Conference Call to be Held on November 27, 20
November 26, 2019	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
October 29, 2019	EX-99.1	GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 5, 2019 (or any Exhibit 99.1 GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 5, 2019 (or any adjourned or postponed meeting thereof) To the Shareholders of Global Cord Blood Corporation: NOTICE IS HEREBY GIVEN that the 2019 Annua
October 29, 2019	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 a19-2079916k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden
October 8, 2019	CORRESP	CO / China Cord Blood Corp. CORRESP - - CORRESP 1 filename1.htm Global Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road, Central Hong Kong S.A.R. October 9, 2019 Ronald Alper Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Global Cord Blood Corporation Registration Statement on Form F-3 File No. 333-233880 Dear Mr. Alper: The Company hereby requests that the effective date and time o
September 23, 2019	F-3	CO / China Cord Blood Corp. F-3 - - F-3 Table of Contents As filed with the Securities and Exchange Commission on September 20, 2019 Registration No.
August 27, 2019	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2020 1Q20 Added 20,815 New Subscribers Revenues Up 16.9% YoY to RMB273.4 Million ($39.8 Million) Gross Profit Up 19.4% YoY to RMB227.6 million ($33.2 million) Ope Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2020 1Q20 Added 20,815 New Subscribers Revenues Up 16.9% YoY to RMB273.4 Million ($39.8 Million) Gross Profit Up 19.4% YoY to RMB227.6 million ($33.2 million) Operating Income Up 17.8% YoY to RMB112.4 Million ($16.4 Million) Non-GAAP Operating Income Up 15.0% YoY to RMB124.8 Million ($18.2 Million)
August 27, 2019	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R
August 14, 2019	EX-13.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Global Cord Blood Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The annual report on Form 20-F/A for the year
August 14, 2019	EX-15.1	Consent of KPMG Huazhen LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors Global Cord Blood Corporation We consent to the incorporation by reference in the Registration Statements (No. 333 -183143 and No. 333 - 213730) on Form F-3 of Global Cord Blood Corporation of our reports dated July 23, 2019, with respect to the consolidated balance sheets of Global Cord Blood Corporation
August 14, 2019	EX-12.1	Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.1 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F/A of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which s
August 14, 2019	20-F/A	our Annual Report on Form 20-F/A for the fiscal year ended March 31, 2019, filed with the SEC on August 14, 2019; Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A Amendment No. 1 o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d
August 14, 2019	EX-12.2	Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.2 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F/A of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
July 23, 2019	EX-12.2	Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.2 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which su
July 23, 2019	EX-15.1	Consent of KPMG Huazhen LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors Global Cord Blood Corporation We consent to the incorporation by reference in the Registration Statements (No. 333 -183143 and No. 333 - 213730) on Form F-3 of Global Cord Blood Corporation of our reports dated July 23, 2019, with respect to the consolidated balance sheets of Global Cord Blood Corporation
July 23, 2019	EX-15.2	Consent of Commerce & Finance Law Offices Exhibit 15.2 通商律師事務所 Commerce & Finance Law Offices 6F NCI Tower, A12 Jianguomenwai Avenue, Chaoyang District, Beijing, PRC; Postcode: 100022 Tel:(8610) 65693399 Fax: (8610) 65693838 Website: www.tongshang.com July 23, 2019 Global Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Dear Sirs/Madams: We consent to the reference of our name under the
July 23, 2019	EX-4.32	Non-binding proposal letter from Cordlife Group Limited, dated June 4, 2019 Exhibit 4.32 Cordlife Group Limited 1 Yishun Industrial Street 1 • A’Posh Bizhub • #06-01/09 • Singapore 768160 Phone (65) 6238 0808 • Fax (65) 6238 1108 Find Out More • [email protected] • For Cordlife Parents • [email protected] Company Registration Number: 200102883E CONFIDENTIAL June 4, 2019 Global Cord Blood Corporation. 48th Floor, Bank of China Tower 1 Garden Road, Central, Hong Kon
July 23, 2019	EX-13.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Global Cord Blood Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The annual report on Form 20-F for the year en
July 23, 2019	EX-12.1	Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.1 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc
July 23, 2019	20-F	our Annual Report on Form 20-F for the fiscal year ended March 31, 2019, filed with the SEC on July 23, 2019; Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE
June 18, 2019	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2019 Added 22,194 New Subscribers in 4Q19 4Q19 Revenues Increased by 8.0% YoY to RMB251.7 Million ($37.5 Million) 4Q19 Operating Income Increased t Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2019 Added 22,194 New Subscribers in 4Q19 4Q19 Revenues Increased by 8.0% YoY to RMB251.7 Million ($37.5 Million) 4Q19 Operating Income Increased to RMB88.9 Million ($13.2 Million) Conference Call to be Held on June 19, 2019 at 8:00 a.m. ET HONG KONG, China, June 18, 2019 — Global Co
June 18, 2019	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 a19-1148716k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Roa
June 6, 2019	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 a19-1117916k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Roa
June 6, 2019	EX-99.1	Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal Exhibit 99.1 Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal HONG KONG, China, June 6, 2019 — Global Cord Blood Corporation (NYSE: CO) (the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-binding
June 4, 2019	6-K	CO / China Cord Blood Corp. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 a19-1105516k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Roa
June 4, 2019	EX-99.1	Global Cord Blood Corporation Announces Receipt of Preliminary Non-Binding Proposal to Acquire the Company Exhibit 99.1 Global Cord Blood Corporation Announces Receipt of Preliminary Non-Binding Proposal to Acquire the Company HONG KONG, China, June 4, 2019 — Global Cord Blood Corporation (NYSE: CO) (the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors has rec
February 25, 2019	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2019 3Q19 Added 23,663 New Subscribers Revenues Up 3.7% YoY to RMB254.2 Million ($37.0 Million) Operating Income Increased to RMB92.6 Millio Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2019 3Q19 Added 23,663 New Subscribers Revenues Up 3.7% YoY to RMB254.2 Million ($37.0 Million) Operating Income Increased to RMB92.6 Million ($13.5 Million) Conference Call to be Held on February 26, 2019 at 8:00 a.m. ET HONG KONG, China, February 25, 2019 — Global Cord Blood
February 25, 2019	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a19-499716k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden
February 14, 2019	SC 13G/A	CO / China Cord Blood Corp. / JAYHAWK CAPITAL MANAGEMENT, L.L.C. - SC 13GA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment No. 14 Under the Securities Exchange Act of 1934* Global Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 698659109 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
December 7, 2018	6-K/A	CO / China Cord Blood Corp. 6-K/A (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road C
December 6, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A
December 6, 2018	EX-99.1	Global Cord Blood Corporation Announces Results of 2018 Annual General Meeting Exhibit 99.1 Global Cord Blood Corporation Announces Results of 2018 Annual General Meeting HONG KONG, China, December 5, 2018 - Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2018 Annual General Meeting,
November 27, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-4060616k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden
November 27, 2018	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2019 2Q19 Added 22,908 New Subscribers Revenues Up 5.3% YoY to RMB247.1 Million ($36.0 Million) Operating Income Up 37.3% YoY to RMB104.8 Million Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2019 2Q19 Added 22,908 New Subscribers Revenues Up 5.3% YoY to RMB247.1 Million ($36.0 Million) Operating Income Up 37.3% YoY to RMB104.8 Million ($15.3 Million) Non-GAAP Operating Income Up 8.7% YoY to RMB118.2 Million ($17.2 Million) Conference Call to be Held on November 28, 2018
October 30, 2018	EX-99.1	GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 5, 2018 (or any Exhibit 99.1 GLOBAL CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 5, 2018 (or any adjourned or postponed meeting thereof) To the Shareholders of Global Cord Blood Corporation: NOTICE IS HEREBY GIVEN that the 2018 Annua
October 30, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-3723916k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden
August 23, 2018	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2019 1Q19 Added 20,601 New Subscribers Revenues Increased to RMB233.8 Million ($35.3 Million) Operating Income Up 15.0% YoY to RMB95.4 Million ($14.4 Million) Non Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2019 1Q19 Added 20,601 New Subscribers Revenues Increased to RMB233.8 Million ($35.3 Million) Operating Income Up 15.0% YoY to RMB95.4 Million ($14.4 Million) Non-GAAP Operating Income Up 17.7% YoY to RMB108.6 Million ($16.4 Million) Conference Call to be Held on August 24, 2018 at 8:00 a.m. ET HON
August 23, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-1907816k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden R
August 17, 2018	EX-99.1	Global Cord Blood Corporation Announces the Results of Scrip Dividend Elections Exhibit 99.1 Global Cord Blood Corporation Announces the Results of Scrip Dividend Elections HONG KONG, China, August 17, 2018 - Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of the scrip dividend elections. The
August 17, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-1895316k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden R
August 6, 2018	SC 13D/A	VTR / Ventas, Inc. / Magnum Opus International (PTC) Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Global Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 (Title of Class of Securities) G39342103 (CUSIP Number) Albert Chen c/o Magnum Opus International (PTC) Limited 48th Floor, Bank of China Tower 1 Garden Road, Central Hong
July 23, 2018	EX-15.2	Consent of Zhong Lun Law Firm Exhibit 15.2 Date: July 23, 2018 Global Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Madams and Sirs, We hereby consent to the use of our name under the captions “Enforceability of Civil Liabilities”, “Legal Matters” and “Experts” in the registration statement on Form F-3 (the “Registration Statement”) filed by Global Cord Blood Corporation (the “Co
July 23, 2018	EX-15.3	Scrip Dividend Scheme Exhibit 15.3 Scrip Dividend Scheme — June 2018 GLOBAL CORD BLOOD CORPORATION (NYSE:CO) DISCLAIMER Forward Looking Statements This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has
July 23, 2018	EX-13.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Global Cord Blood Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The annual report on Form 20-F for the year en
July 23, 2018	EX-12.2	Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.2 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which su
July 23, 2018	EX-15.1	Consent of KPMG Huazhen LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors Global Cord Blood Corporation We consent to the incorporation by reference in the registration statements (No. 333 -183143 and No. 333 - 213730) on Form F-3 of Global Cord Blood Corporation (formerly known as China Cord Blood Corporation) of our reports dated July 23, 2018, with respect to the consolidated
July 23, 2018	EX-12.1	Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended Exhibit 12.1 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of Global Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc
July 23, 2018	20-F	CO / China Cord Blood Corp. 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE
June 26, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-1577316k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 Commission File Number: 001-34541 GLOBAL CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Roa
June 26, 2018	EX-99.1	Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 Added 21,390 New Subscribers in 4Q18 4Q18 Revenues Amounted to RMB233.0 Million ($37.1 Million) 4Q18 Operating Income Amounted to RMB42.2 Mill Exhibit 99.1 Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 Added 21,390 New Subscribers in 4Q18 4Q18 Revenues Amounted to RMB233.0 Million ($37.1 Million) 4Q18 Operating Income Amounted to RMB42.2 Million ($6.7 Million) 4Q18 Non-GAAP Operating Income Amounted to RMB102.9 Million ($16.4 Million) Board Declared Dividend of $0.08 per ordin
March 16, 2018	EX-99.1	China Cord Blood Corporation Announces Results of Extraordinary General Meeting of Shareholders to Change Company Name to “Global Cord Blood Corporation” Exhibit 99.1 China Cord Blood Corporation Announces Results of Extraordinary General Meeting of Shareholders to Change Company Name to “Global Cord Blood Corporation” HONG KONG, China, March 16, 2018 - China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), a leading cord blood banking operator in China, today announced the results of its extraordinary general meeting of shareholders, w
March 16, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-843316k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road
February 28, 2018	EX-99.1	CHINA CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Hong Kong S.A.R. NOTICE OF EXTRAORDINARY GENERAL MEETING to Be Held on March 16, 2018 (or any adj Exhibit 99.1 CHINA CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF EXTRAORDINARY GENERAL MEETING to Be Held on March 16, 2018 (or any adjourned or postponed meeting thereof) To the Shareholders of China Cord Blood Corporation: NOTICE IS HEREBY GIVEN that an extraord
February 28, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-599716k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden R
February 26, 2018	EX-99.1	China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2018 3Q18 Added 24,229 New Subscribers 3Q18 Revenues Up 22.0% YOY to RMB245.0 Million ($37.7 Million) 3Q18 Operating Income Reached RMB78.4 M Exhibit 99.1 China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2018 3Q18 Added 24,229 New Subscribers 3Q18 Revenues Up 22.0% YOY to RMB245.0 Million ($37.7 Million) 3Q18 Operating Income Reached RMB78.4 Million ($12.0 Million) Conference Call to be Held on February 27, 2018 at 8:00 a.m. ET HONG KONG, China, February 26, 2018 ? China Cord B
February 26, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.
February 14, 2018	SC 13G/A	CO / China Cord Blood Corp. / JAYHAWK CAPITAL MANAGEMENT, L.L.C. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment No. 13 Under the Securities Exchange Act of 1934* China Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 698659109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 8, 2018	SC 13D	CO / China Cord Blood Corp. / Blue Ocean Structure Investment Co Ltd - SC 13D Activist Investment SC 13D 1 a18-55551sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CHINA CORD BLOOD CORPORATION (Name of Issuer) Ordinary Shares, par value US$0.0001 per share (Title of Class of Securities) G21107100 (CUSIP Number) Pengfei Huo No. 68 Software Avenue, Yuhuatai District Nanjing, China +86-25-83274711 (Nam
February 8, 2018	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the ordinary shares of China Cord Blood Corporation and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filing.
January 31, 2018	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a18-385916k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Ro
January 31, 2018	EX-99.1	Nanjing Ying Peng Becomes Major Shareholder of China Cord Blood Corporation Exhibit 99.1 Nanjing Ying Peng Becomes Major Shareholder of China Cord Blood Corporation HONG KONG, China, January 31, 2018 ? China Cord Blood Corporation (NYSE: CO) (?CCBC? or the ?Company?), a leading cord blood bank operator in China, today announced that Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership) (?Nanjing Ying Peng?), via its subsidiary, has becom
January 31, 2018	SC 13D/A	CO / China Cord Blood Corp. / Golden Meditech Holdings Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 28) China Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21107100 (CUSIP Number) Yuen Kam 48th Floor, Bank of China Tower 1 Garden Road, Central Hong Kong S.A.R. (852) 3605-8180 (Name, A
December 7, 2017	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) 6-K 1 a17-2784016k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden
December 7, 2017	EX-99.1	China Cord Blood Corporation Announces Results of 2017 Annual General Meeting Exhibit 99.1 China Cord Blood Corporation Announces Results of 2017 Annual General Meeting HONG KONG, China, December 7, 2017 - China Cord Blood Corporation (NYSE: CO) (?CCBC? or the ?Company?), China?s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2017 Annual General Meeting, wh
December 6, 2017	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commissio UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden Road Ce
November 20, 2017	6-K	CO / China Cord Blood Corp. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.
November 20, 2017	EX-99.1	China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2018 2Q18 Added 23,647 New Subscribers 2Q18 Revenues Up 27.4% YOY to RMB234.6 Million ($35.3 Million) 2Q18 Operating Income Up 39.4% YOY to RMB76.3 Exhibit 99.1 China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2018 2Q18 Added 23,647 New Subscribers 2Q18 Revenues Up 27.4% YOY to RMB234.6 Million ($35.3 Million) 2Q18 Operating Income Up 39.4% YOY to RMB76.3 Million ($11.5 Million) Conference Call to be Held on November 21, 2017 at 8:00 a.m. ET HONG KONG, China, November 20, 2017 ? China Cord
November 14, 2017	EX-99.54	Supplemental Agreement to Share Purchase Agreement In relation to China Cord Blood Corporation By and among Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership) Golden Meditech Stem Cells (BVI) Company Limited Gold Exhibit 54 Confidential English Translation of Chinese Original Supplemental Agreement to Share Purchase Agreement In relation to China Cord Blood Corporation By and among Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership) and Golden Meditech Stem Cells (BVI) Company Limited and Golden Meditech Holdings Limited Dated: November 14, 2017 This Supplemental Agreem
November 14, 2017	SC 13D/A	CO / China Cord Blood Corp. / Golden Meditech Holdings Ltd - SC 13D/A Activist Investment SC 13D/A 1 a17-270731sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 27) China Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21107100 (CUSIP Number) Yuen Kam 48th Floor, Bank of China Tower 1 Garden Road, Central
October 31, 2017	6-K	China Cord Blood 6-K (Current Report of Foreign Issuer) 6-K 1 a17-2434516k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48th Floor, Bank of China Tower 1 Garden R
October 31, 2017	EX-99.1	CHINA CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 7, 2017 (or any adjourne Exhibit 99.1 CHINA CORD BLOOD CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: CO) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 7, 2017 (or any adjourned or postponed meeting thereof) To the Shareholders of China Cord Blood Corporation: NOTICE IS HEREBY GIVEN that the 2017 Annual
August 23, 2017	6-K	China Cord Blood 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant?s name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R.
August 23, 2017	EX-99.1	China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2018 1Q18 Added 22,523 New Subscribers 1Q18 Revenues Up 29.6% YOY to RMB224.2 Million ($33.1 Million) 1Q18 Operating Income Reached RMB83.0 Million ($12.2 Million) Exhibit 99.1 China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2018 1Q18 Added 22,523 New Subscribers 1Q18 Revenues Up 29.6% YOY to RMB224.2 Million ($33.1 Million) 1Q18 Operating Income Reached RMB83.0 Million ($12.2 Million) Conference Call to be Held on August 24, 2017 at 8:00 a.m. ET HONG KONG, China, August 23, 2017 ? China Cord Blood Corporation (NYSE: CO
July 25, 2017	EX-12.1	Certification Pursuant to Rule 13a-14(a) of the Exchange Act Exhibit 12.1 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
July 25, 2017	EX-15.2	Consent of Independent Registered Public Accounting Firm EX-15.2 7 a17-103211ex15d2.htm EX-15.2 Exhibit 15.2 Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation: We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-213730 on Form F-3 of China Cord Blood Corporation of our reports dated July 25, 2017, with respect to the consolidated balance sheets
July 25, 2017	EX-12.2	Certification Pursuant to Rule 13a-14(a) of the Exchange Act Exhibit 12.2 Certification Pursuant to Rule 13a-14(a) of the Exchange Act I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc
July 25, 2017	EX-15.3	China Cord Blood Corporation EX-15.3 8 a17-103211ex15d3.htm EX-15.3 Exhibit 15.3 Date: July 25, 2017 China Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Madams and Sirs, We hereby consent to the use of our name under the captions “Enforceability of Civil Liabilities”, “Legal Matters” and “Experts” in the registration statements on Form F-3 (the “Registration Statement”) filed by
July 25, 2017	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE
July 25, 2017	EX-13.1	Certification Pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China Cord Blood Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The annual report on Form 20-F for the year end
July 25, 2017	EX-15.1	Consent of Independent Registered Public Accounting Firm EX-15.1 6 a17-103211ex15d1.htm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation: We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-213730 on Form F-3 of China Cord Blood Corporation of our report dated July 31, 2015, with respect to the consolidated statements of co
June 21, 2017	EX-99.1	China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2017 Added 20,566 New Subscribers in 4Q17 4Q17 Revenue Amounted to RMB202.0 Million ($29.3 Million) 4Q17 Operating Income Amounted to RMB56.3 Millio Exhibit 99.1 China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2017 Added 20,566 New Subscribers in 4Q17 4Q17 Revenue Amounted to RMB202.0 Million ($29.3 Million) 4Q17 Operating Income Amounted to RMB56.3 Million ($8.2 Million) Conference Call to be Held on June 22, 2017 at 8:00 a.m. ET HONG KONG, China, June 21, 2017 ? China Cord Blood Corporati
June 21, 2017	6-K	China Cord Blood 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrants name into English) 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. (
April 13, 2017	EX-99.1	China Cord Blood Corporation Announces Termination of Evaluation and Negotiation Regarding “Going Private” Proposal Exhibit 99.1 China Cord Blood Corporation Announces Termination of Evaluation and Negotiation Regarding ?Going Private? Proposal HONG KONG, China, April 13, 2017 ? China Cord Blood Corporation (NYSE: CO) (?CCBC? or the ?Company?), China?s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in respons
April 13, 2017	6-K	China Cord Blood 6-K (Current Report of Foreign Issuer) 6-K 1 a17-1133216k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2017 Commission File Number: 001-34541 CHINA CORD BLOOD CORPORATION (Translation of registrant’s name into English) 48thFloor, Bank of China Tower 1 Garden Road
April 13, 2017	SC 13D/A	CO / China Cord Blood Corp. / Golden Meditech Holdings Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 26) China Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21107100 (CUSIP Number) Yuen Kam 48th Floor, Bank of China Tower 1 Garden Road, Central Hong Kong S.A.R. (852) 3605-8180 (Name, A
April 13, 2017	EX-99.53	The Board of Directors Exhibit 53 April 13, 2017 The Board of Directors Golden Meditech Holdings Limited 48/F.
April 10, 2017	SC 13D/A	CO / China Cord Blood Corp. / Golden Meditech Holdings Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 25) China Cord Blood Corporation (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21107100 (CUSIP Number) Yuen Kam 48th Floor, Bank of China Tower 1 Garden Road, Central Hong Kong S.A.R. (852) 3605-8180 (Name, A
April 10, 2017	EX-99.52	JOINT FILING AGREEMENT Exhibit 52 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares of China Cord Blood Corporation, a Cayman Islands company, and further agree that this Joint Filing Agreement may be included as an Exhibit to such joint filing.

CO / Global Cord Blood Corp - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)